Navigation Links
USC researchers identify novel approach for suppressing prostate cancer development
Date:11/24/2008

Los Angeles, Calif. Nov. 24, 2008Researchers at the University of Southern California (USC) have found that inactivating a specific biomarker for aggressive prostate cancer blocks the development of prostate cancer in animal models.

Researchers say the upcoming study in the Proceedings of the National Academy of Sciencesnow available onlinemay lead to a novel cancer therapy for humans.

"This research has far-reaching implications in a wide range for human cancers," says Amy Lee, Ph.D., the study's principal investigator and the associate director for basic research and holder of the Freeman Cosmetics Chair at the USC/Norris Comprehensive Cancer Center, and professor of biochemistry and molecular biology at the Keck School of Medicine of USC. "It is a breakthrough study."

Prostate cancer is the most common cancer in men and develops through successive stages. The glucose-regulated protein GRP78 has been identified as a crucial entity in the development of prostate cancer by promoting cancer cell proliferation, mediating oncogenic signaling and protecting cancer cells against cell death resulting from the stress of tumor development, Lee explains. By suppressing GRP78 expression or activity, the USC researchers found that they could block prostate cancer activation and development resulting from the loss of PTEN, a powerful tumor suppressor gene for a number of human cancers.

Researchers spent more than three years monitoring prostate cancer development in animal models that had been genetically engineered to have both the GRP78 and PTEN tumor suppressor genes inactivated. The research was conducted by Yong Fu, a Ph.D. candidate at the Keck School of Medicine of USC and the first author on the study, in collaboration with Ph.D candidates Shiuan Wey, Miao Wang, Risheng Ye and Chun-Peng Liao and Pradip Roy-Burman, M.D., professor of pathology, biochemistry and molecular biology at the Keck School.

Future research should test the role of GRP78 in other types of cancer and isolate drugs that inhibit GRP78, Lee says. "To our knowledge, this is the first demonstration that inactivation of a specific molecular chaperone from the mouse prostate epithelial cells can potently block prostate cancer development and suppress the activation of AKT, which is a protein kinase that promotes cell proliferation and survival and is a major factor in many types of cancer," Lee says. "With the recent advances in identifying agents that suppress GRP78 expression, anti-GRP78 therapy may open up an entirely new approach to stop human cancer."


'/>"/>

Contact: Meghan Lewit
lewit@usc.edu
323-442-3941
University of Southern California
Source:Eurekalert

Related medicine news :

1. Researchers identify new leprosy bacterium
2. UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs
3. Researchers discover strategy for predicting the immunity of vaccines
4. Ability to quit smoking may depend on ADHD symptoms, Columbia researchers find
5. Researchers ID Suite of Genes in Aging Process
6. Researchers: Ban on fast food TV advertising would reverse childhood obesity trends
7. Brigham and Womens Researchers Partner with Vocantas to use CallAssure in Clinical Research Study
8. Leeds researchers reshape the future of drug discovery
9. UNC researchers find clue to stopping breast-cancer metastasis
10. U of U researchers to use patients own stem cells to treat heart failure
11. Researchers identify toehold for HIVs assault on brain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... ... feature 150+ Hospital and Health System Executive Speakers including: , , ... of the United States of America: George W. Bush , Boxing Legend, Successful ... Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber McGraw Walsh , ...
(Date:3/23/2017)... ... 23, 2017 , ... Sharon Kleyne, host of the nationally syndicated radio program, ... VoiceAmerica, recently talked on her program about how she is looking forward to World ... of an important distinction. World Water Day, Kleyne pointed out, is an occasion for ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... improve all aspects of people’s health and nutrition, announced its product Leyzene is ... , Natural Subsistence develops nutritional supplements that help people improve all aspects of ...
(Date:3/23/2017)... ... 23, 2017 , ... Inflow IQ & Inflownomics of Raleigh, NC introduce a ... solid foundation. As experts in dangerous situations the Inflow IQ team can help ... deliver ripe, fresh, clean & refreshing knowledge systems that enhance life. , ...
(Date:3/23/2017)... ... March 23, 2017 , ... The American Board of Quality Assurance and Utilization ... ABQAURP’s dedication to Health Care Quality and Management and Patient Safety. , It is ... the association, but also to the Health Care Quality and Patient Safety movements. Diplomates ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... March 23, 2017  The goal of the ... identify and track prescription drugs as they are distributed ... response to requirements from US FDA to better protect ... dangerous medicines. Blockchain startup Chronicled, which ... chips and blockchain technology and recently raised $6.25M, and ...
(Date:3/23/2017)... 2017 The global reprocessed ... the top five players accounting for nearly 94% ... are Stryker Sustainability Solutions, Ethicon (Johnson & Johnson), ... VANGUARD AG. Despite the high level of consolidation, ... the prevalence of fierce competition among the key ...
(Date:3/23/2017)... -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) today ... Phase 1 study of MM-310 in solid tumors. MM-310 ... taxane and targets the EphA2 receptor, a protein which ... tumor types, including prostate, ovarian, bladder, gastric, pancreatic and ... is an important step in evaluating MM-310,s safety and ...
Breaking Medicine Technology: